| Code | Description | Claims | Beneficiaries | Total Paid |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
13,879 |
12,781 |
$5.26M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
12,529 |
11,855 |
$2.37M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
3,990 |
3,676 |
$1.02M |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
4,648 |
4,122 |
$386K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
1,603 |
1,408 |
$271K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
2,605 |
2,540 |
$253K |
| 67028 |
Intravitreal injection of a pharmacologic agent |
876 |
746 |
$218K |
| 36415 |
Collection of venous blood by venipuncture |
21,382 |
18,989 |
$190K |
| G0378 |
Hospital observation service, per hour |
3,247 |
1,290 |
$140K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,504 |
1,438 |
$95K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
20,409 |
17,619 |
$92K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
340 |
333 |
$90K |
| 77080 |
|
156 |
147 |
$72K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
3,542 |
2,885 |
$70K |
| J0248 |
Injection, remdesivir, 1 mg |
117 |
45 |
$66K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
3,420 |
3,310 |
$66K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
828 |
432 |
$52K |
| D0150 |
Comprehensive oral evaluation - new or established patient |
56 |
51 |
$50K |
| Q0222 |
Injection, bebtelovimab, 175 mg |
38 |
38 |
$49K |
| M0222 |
Intravenous injection, bebtelovimab, includes injection and post administration monitoring |
198 |
197 |
$46K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
316 |
312 |
$42K |
| M0247 |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring |
207 |
201 |
$41K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
455 |
374 |
$31K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,504 |
1,438 |
$31K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
4,551 |
3,855 |
$30K |
| M0245 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
104 |
102 |
$30K |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
89 |
76 |
$28K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
2,493 |
1,898 |
$28K |
| 95782 |
|
37 |
36 |
$25K |
| 87631 |
|
851 |
825 |
$23K |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
27 |
27 |
$22K |
| 71046 |
Radiologic examination, chest; 2 views |
819 |
786 |
$22K |
| 93325 |
|
710 |
569 |
$20K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
104 |
93 |
$16K |
| 80053 |
Comprehensive metabolic panel |
1,687 |
1,150 |
$13K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
296 |
283 |
$13K |
| M0239 |
Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring |
77 |
66 |
$12K |
| 97597 |
|
90 |
77 |
$11K |
| 82565 |
|
1,117 |
857 |
$8K |
| A9270 |
Non-covered item or service |
2,655 |
1,542 |
$8K |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
53 |
48 |
$8K |
| 91200 |
|
70 |
70 |
$8K |
| D9420 |
|
57 |
51 |
$7K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
540 |
84 |
$7K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,684 |
1,253 |
$5K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
24 |
22 |
$5K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
171 |
142 |
$5K |
| 93320 |
|
27 |
25 |
$5K |
| 83605 |
|
739 |
671 |
$5K |
| J0475 |
Injection, baclofen, 10 mg |
12 |
12 |
$5K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
83 |
69 |
$4K |
| 70450 |
Computed tomography, head or brain; without contrast material |
76 |
72 |
$4K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
3,272 |
2,635 |
$4K |
| J2704 |
Injection, propofol, 10 mg |
14,642 |
4,660 |
$4K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
62 |
62 |
$4K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
3,361 |
2,251 |
$4K |
| 82947 |
|
2,273 |
1,411 |
$4K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
3,028 |
2,391 |
$3K |
| C9257 |
Injection, bevacizumab, 0.25 mg |
184 |
154 |
$3K |
| 71045 |
Radiologic examination, chest; single view |
435 |
309 |
$3K |
| 83935 |
|
106 |
92 |
$3K |
| D1120 |
Prophylaxis - child |
25 |
24 |
$3K |
| D1206 |
Topical application of fluoride varnish |
26 |
25 |
$3K |
| 0753T |
|
328 |
292 |
$3K |
| 82948 |
|
1,082 |
402 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
3,233 |
2,644 |
$2K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
6,375 |
4,443 |
$2K |
| 85610 |
|
720 |
510 |
$2K |
| 82248 |
|
655 |
557 |
$2K |
| 77336 |
|
33 |
12 |
$2K |
| C1769 |
Guide wire |
914 |
787 |
$1K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
2,716 |
1,891 |
$1K |
| 62370 |
|
12 |
12 |
$1K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
4,206 |
2,168 |
$1K |
| J3490 |
Unclassified drugs |
1,094 |
668 |
$1K |
| 84484 |
|
127 |
109 |
$1K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
69 |
53 |
$1K |
| 83735 |
|
249 |
123 |
$1K |
| 36591 |
|
95 |
51 |
$894.09 |
| 88342 |
|
105 |
93 |
$815.35 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
514 |
327 |
$785.28 |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
13 |
13 |
$634.62 |
| 84132 |
|
197 |
89 |
$604.39 |
| 80051 |
|
672 |
593 |
$530.40 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
351 |
224 |
$483.49 |
| 84443 |
Thyroid stimulating hormone (TSH) |
57 |
49 |
$482.58 |
| 85027 |
|
141 |
115 |
$472.28 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
725 |
322 |
$422.63 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,708 |
913 |
$341.52 |
| 83690 |
|
84 |
76 |
$324.79 |
| 84520 |
|
759 |
664 |
$324.34 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
15 |
14 |
$318.94 |
| 87634 |
|
28 |
28 |
$302.33 |
| J1644 |
Injection, heparin sodium, per 1000 units |
740 |
365 |
$265.35 |
| 84295 |
|
64 |
39 |
$242.57 |
| 84450 |
|
66 |
51 |
$220.74 |
| 87070 |
|
62 |
49 |
$219.27 |
| 81001 |
|
106 |
92 |
$217.01 |
| 82077 |
|
13 |
13 |
$215.46 |
| 82803 |
|
25 |
24 |
$213.86 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
248 |
186 |
$207.30 |
| 74018 |
|
38 |
25 |
$205.64 |
| 84702 |
|
58 |
53 |
$201.99 |
| 84075 |
|
47 |
38 |
$126.81 |
| J7050 |
Infusion, normal saline solution, 250 cc |
1,173 |
901 |
$117.27 |
| 88313 |
|
13 |
13 |
$116.14 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
27 |
25 |
$100.38 |
| 87205 |
|
27 |
24 |
$74.25 |
| 82247 |
|
26 |
25 |
$34.99 |
| J1790 |
Injection, droperidol, up to 5 mg |
34 |
28 |
$34.05 |
| 77091 |
|
14 |
13 |
$30.64 |
| J1630 |
Injection, haloperidol, up to 5 mg |
28 |
25 |
$18.54 |
| 87206 |
|
17 |
12 |
$16.71 |
| 81003 |
|
12 |
12 |
$14.82 |
| 88307 |
|
15 |
13 |
$13.02 |
| 85379 |
|
13 |
12 |
$10.52 |
| Q9969 |
Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose |
46 |
37 |
$7.42 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
404 |
325 |
$1.10 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
280 |
217 |
$0.03 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
132 |
88 |
$0.02 |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
13 |
13 |
$0.00 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
15 |
13 |
$0.00 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
27 |
16 |
$0.00 |
| C9290 |
Injection, bupivacaine liposome, 1 mg |
18 |
12 |
$0.00 |